ASTROCYTE PHARMACEUTICALS INC.

Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, traumatic brain injury (TBI), concussion, and neurodegenerative disorders such as Alzheimer's disease. Its lead candidate, AST-004, is a novel adenosine A1/A3 receptor agonist that demonstrates significant cerebroprotective efficacy across a broad range of acute brain injury models. AST-004 received FDA clearance of its Investigational New Drug Application in March 2024, and a Phase 2 clinical trial was launched in June 2025. The company has received multiple SBIR/STTR grants from the NIH and Department of Defense.